Home › News › Global Pharma

Roche's Wilserdly Receives US FDA Approval for Advanced Breast Cancer

Roche's Wilserdly Receives US FDA Approval for Advanced Breast Cancer

Roche announced that the US Food and Drug Administration (FDA) has approved Wilserdly (giredestrant) in combination with everolimus for treating adults with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer. The approval covers patients whose disease has progressed following endocrine-based treatment.

The approval is supported by results from the Phase 3 evERA Breast Cancer study, published in The New England Journal of Medicine. The study demonstrated that Wilserdly combined with everolimus reduced the risk of disease progression or death by 62 percent compared with standard endocrine therapy combined with everolimus in patients with ESR1-mutated breast cancer who had previously received CDK4/6 inhibitor therapy.

Wilserdly is an oral selective oestrogen receptor degrader designed to block oestrogen signalling and promote the breakdown of oestrogen receptors. When combined with everolimus, it targets two different signalling pathways involved in cancer progression and treatment resistance.

According to Roche, ESR1 mutations develop in up to 40 percent of patients with hormone receptor-positive metastatic breast cancer and are associated with resistance to endocrine therapy. The newly approved combination provides an additional all-oral treatment option for these patients.

Separately, Roche has submitted a New Drug Application for Wilserdly as an adjuvant treatment for adults with ER-positive, HER2-negative early-stage breast cancer at intermediate to high risk of recurrence. The application has been accepted for Priority Review by the FDA, with a target decision date of November 30, 2026.

More news about: global pharma | Published by News Bureau | November - 18 - 2026

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members